BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
